Provides clinical practice recommendations for early initiation of RAAS interference in children with Alport syndrome to reduce proteinuria and renal fibrosis.
Supports early RAAS blockade in pediatric Alport syndrome; extends adult evidence to guide practice and slow progression.
We present clinical practice recommendations for the treatment of children with Alport syndrome who are not enrolled in clinical trials. Our goal is to promote early initiation of a standard therapeutic approach that will facilitate assessment of the safety and efficacy of the protocol. The treatment protocol is based on the reduction of proteinuria, intraglomerular pressure, and renal fibrosis via interference with the renin-angiotensin-aldosterone system.
No takes yet. Share an insight, caveat, or question.
Kashtan et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: